Apsara Medical Corporation

Calfacior Corporation

Mitsubishi Heavy Industries Limited

Parhelion Incorporated

Apsara, Inc.

Apasara Medical Corporation

Calfacion Corporation

Cira Technologies, Inc.

John L Ridihalgh

Philip E Eggers

Gary Altman

Mark Mayerchak

Elmer C Lusk

Richard G Olsen

Method, system and apparatus for monitoring target tissue temperatures wherein temperature sensors are configured as passive resonant circuits each with a unique resonating signature at monitoring temperatures extending below a select temperature setpoint. The resonant circuits are configured with an inductor component formed of windings about a ferrite core having a Curie temperature characteristic corresponding with a desired temperature setpoint. By selecting inductor winding turns and capacitance values, unique resonant center frequencies are detectable. Temperature monitoring can be carried out with implants at lower threshold and upper limit temperature responses. Additionally, the lower threshold sensors may be combined with auto-regulated heater implants having Curie transitions at upper temperature limits.

System, method and apparatus for evaluating tissue temperature

System method and apparatus for accurately carrying out the in situ heating of a targeted tissue. Small implants are employed with the targeted tissue which exhibit an abrupt change of magnetic permeability at an elected Curie temperature. The permeability state of the implant is monitored utilizing a magnetometer. The implants may be formed as a setpoint temperature determining component combined with a non-magnetic heater component to enhance the tissue heating control of the system. With the system, a very accurate quantum of heat energy can be supplied to a neoplastic lesion or tissue carrying infectious disease so as to maximize the induction of heat shock proteins. The system also may be utilized in conjunction with non-magnetic arterially implanted stents for the hyperthermia therapy treatment of restenosis and in conjunction with the mending of boney tissue.

System method and apparatus for localized heating of tissue

Method, system and apparatus for monitoring target tissue temperatures wherein temperature sensors are configured as passive resonant circuits each, with a unique resonating signature at monitoring temperatures extending below a select temperature setpoint. The resonant circuits are configured with an inductor component formed of windings about a ferrite core having a Curie temperature characteristic corresponding with a desired temperature setpoint. By selecting inductor winding turns and capacitance values, unique resonant center frequencies are detectable. Temperature monitoring can be carried out with implants at lower threshold and upper limit temperature responses. Additionally, the lower threshold sensors may be combined with auto-regulated heater implants having Curie transitions at upper temperature limits.

Broadly, disclosed is a novel approach to the treatment of chronic fatigue syndrome (CFS) that exploits the effective cellular immune response that is initially generated in CFS individuals. One aspect is a method for preparing cells for treating patients afflicted with CFS, which includes subjecting cytokine-producing cells derived from lymph nodes excised from patients afflicted with CFS to mitogenic stimulation in serum-free media for their expansion. The resulting therapeutic agent for treating patients afflicted with CFS includes in a pharmaceutically-acceptable carrier cytokine-producing having been produced by the step of subjecting cells derived from lymph nodes excised from patients afflicted with CFS to mitogenic stimulation in serum-free media for their expansion. As another aspect of the present invention, disclosed is a method for treating patients afflicted with CFS that includes administering to the patient an effective amount of the therapeutic agent disclosed herein. The invention also is capable of treating individuals afflicted with fibromyalgia syndrome (&ldquo;FMS&rdquo;). Finally, the invention further is effective in lowering activated T cell count in individuals.

Cellular immunotherapy treatment of patients afflicted with chronic fatigue syndrome

The present invention broadly relates to a therapeutic agent effective in mitigating disease associated with Feline Leukemia Virus (FeLV) in a feline infected with FeLV. A feline is an animal of the family Felidae. The novel therapeutic agent is composed of feline excised lymph nodes which have been subjected to mitogenic stimulation for their expansion dispersed in a pharmaceutically-acceptable carrier. Mitogenic stimulation conditions include culturing the excised lymph nodes in the presence of Interleukin-2. Optionally, culture conditions can include the presence of allogeneic or autologous FeLV tumor. The inventive therapeutic agent is prepared by excising lymph nodes from a feline infected the FeLV, mitogenically stimulating said excised lymph nodes for their expansion, and administering to the infected feline the expanded lymph nodes. Multidose regimens can be used as is necessary or desirable in convenient fashion. The method for mitigating disease associated with Feline Leukemia Virus (FeLV) in a feline infected with FeLV is composed of administering to the diseased feline the therapeutic agent composed of feline excised lymph nodes which have been subjected to mitogenic stimulation for their expansion dispersed in a pharmaceutically-acceptable carrier.

FeLV therapeutic agent, method of its preparation, and method of

A shipping and transport cask for spent nuclear fuel elements. The cask includes a cylindrical cask body having an outer shell and a concentric inner tube. Four quadrant baskets are mounted within the inner tube. Each quadrant basket includes radial and peripheral walls of high thermal conductivity material. A plurality of fuel element-receiving modules and an inner quadrant heat conducting member are mounted within the quadrant baskets. The peripheral walls of the quadrant baskets are held firmly against the inner wall of the body by shims inserted between the radial walls of adjacent quadrant baskets. During assembly, the quadrant baskets are initially forced outwardly against the inner wall by means of expandable spreaders. The cask also includes removable trunnions and primary and secondary external fluid chambers filled with a neutron-attenuating fluid. A siphon tube interconnects the chambers so that the primary chamber which surrounds the major portion of the cask remains filled despite changes in temperature of the fluid.

Growing community of inventors

Columbus, OH, United States of America

John L Ridihalgh